FS-102 by F-star Therapeutics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

FS-102 is under clinical development by F-star Therapeutics and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction.

The contribution of transcription factor ROB1 to the pathophysiology of C. albicans-induced candidal infections

Researchers evaluated the function of the zinc finger transcription factor ROB1 and its two phenotypically distinct alleles in the pathogenesis of Candida albicans infections.

June 20, 2023

Opinion | How to (Legally) Diversify the Healthcare Workforce

Lazarus is an adjunct professor of psychiatry and a regular commentator on the practice of medicine. The American Medical Association (AMA) has long recognized the

August 30, 2023

Study reveals patterns of high blood pressure in pregnant women, linked to maternal health risks

Research examines the trajectory of systolic blood pressure in pregnant women and its associations with various factors. It sheds light on the patterns and risks

June 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.